Get the Stockscreener App
82.24
3.10%
-2.63
After Hours:
82.14
-0.10
-0.12%
Cytokinetics Inc stock is traded at $82.24, with a volume of 1.89M.
It is down -3.10% in the last 24 hours and up +17.23% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$84.87
Open:
$83.39
24h Volume:
1.89M
Relative Volume:
0.75
Market Cap:
$11.17B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-12.02
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
-3.89%
1M Performance:
+17.23%
6M Performance:
+29.86%
1Y Performance:
+122.21%
1-Day Range:
$80.90
$84.60
1-Week Range:
$80.90
$87.93
52-Week Range:
$32.89
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
82.24 | 11.52B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced? - Yahoo Finance
How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story - Yahoo Finance
Price to sales forward of Cytokinetics, Incorporated – NASDAQ:CYTK - TradingView
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside - TradingView
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A - Stock Titan
CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market - Stock Titan
CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale - Stock Titan
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo By Investing.com - Investing.com Nigeria
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo - Investing.com
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $117 - Moomoo
CYTK Maintained by RBC Capital -- Price Target Lowered to $117 - GuruFocus
RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating - marketscreener.com
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 - The Manila Times
Cytokinetics lands three ESC 2026 presentations on heart drug data - Stock Titan
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of ... - Caledonian Record
CYTKCytokinetics Inc Latest SEC Filings - Finviz
Cytokinetics CEO Robert Blum sells $636,900 in stock - Investing.com UK
Insider Sell Alert: EVP, Chief Financial Officer Sung Lee Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Cytokinetics EVP Andrew Callos sells $1.29 million in shares - Investing.com UK
Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.29 million in shares By Investing.com - Investing.com South Africa
Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale - Stock Titan
Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80 - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79 - Stock Titan
Form 144 CYTOKINETICS For: 1 July By Investing.com - Investing.com UK
CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK) - Stock Titan
Cytokinetics Inc stock hits 52-week high at $88.00 - Investing.com
Cytokinetics Inc stock hits 52-week high at $88.00 By Investing.com - Investing.com India
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Cytokinetics CFO Lee Sung sells $3.18m in company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $3.18m in company stock - Investing.com
Form 144 CYTOKINETICS For: 29 June By Investing.com - Investing.com South Africa
Form 4 Cytokinetics Inc For: 29 June By Investing.com - Investing.com South Africa
Cytokinetics(CYTK.US) Officer Sells US$3.19 Million in Common Stock - Moomoo
Cytokinetics (CYTK) CFO sells 38,730 shares at $82.30 after exercising options - Stock Titan
Cytokinetics CFO Lee Sung sells $266,390 of company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $266,390 of company stock - Investing.com
Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises - Stock Titan
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jul 07 '26 |
Sale |
86.62 |
3,500 |
303,170 |
153,902 |
5.60%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):